Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
SNDX - Syndax Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$38.50
DETAILS
HIGH:
$46.00
LOW:
$31.00
MEDIAN:
$38.50
CONSENSUS:
$38.50
UPSIDE:
68.86%
Stock News
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Syndax Pharmaceuticals NASDAQ: SNDX used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis.
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
Syndax has transitioned into a two-product commercial oncology company with growing revenue and strong cash reserves. Revuforj and Niktimvo drive SNDX's revenue, with Q1 2026 net sales exceeding $100M and significant expansion potential in AML and chronic GVHD. Revuforj's broad FDA approval and post-transplant maintenance potential, alongside Niktimvo's unique mechanism, underpin a multi-billion dollar franchise opportunity.
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients – – Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders – – Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant – – Encouraging durability with median overall survival after transplant not reached – – Combination was generally well-tolerated – NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the Phase 1/2 SAVE trial of an all-oral regimen of Revuforj® (revumenib), decitabine/cedazuridine, and venetoclax in relapsed or refractory (R/R) NPM1 mutated (NPM1m), KMT2A-rearranged (KMT2Ar), or NUP98-rearranged (NUP98r) acute myeloid leukemia (AML) were published in the Journal of Clinical Oncology and simultaneously presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. Revuforj is the first and only menin inhibitor that is FDA approved for patients one year and older with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “Notes”). The sale of the Notes is expected to close on June 10, 2026, subject to customary closing conditions.
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90% vs historical benchmark of 51% –
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City. The R&D Day will feature presentations by Syndax's management team and key opinion leaders.
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
Syndax Announces Participation in Upcoming Investor Conferences
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib monotherapy and combination use – – Two abstracts highlight encouraging results with revumenib in the post-transplant setting – – Frontline and R/R revumenib combination data show deep responses, robust transplant rates, and favorable tolerability – – Encouraging activity observed with revumenib in R/R NUP98r acute leukemia – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted the release of 12 Revuforj® (revumenib) abstracts on the European Hematology Association (EHA) website in advance of the EHA 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden. “The breadth of data accepted for presentation at EHA underscores the strength of revumenib's clinical profile, with activity observed across the acute leukemia treatment continuum in KMT2Ar, NPM1m, and NUP98r acute leukemias,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company granted inducement awards to purchase up to 162,100 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Price Targets
Syndax price target lowered to $31 from $34 at Guggenheim
$31.00
(was $17.91)
Brad Canino
·
Guggenheim
H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
$40.00
(was $18.39)
Andres Maldonado
·
H.C. Wainwright
Syndax price target raised to $46 from $45 at Stifel
$46.00
(was $19.11)
Stifel Nicolaus
Syndax price target raised to $37 from $35 at Barclays
$37.00
(was $21.43)
Barclays
Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel
$45.00
(was $21.71)
Stephen Willey
·
Stifel Nicolaus
Syndax price target raised to $35 from $22 at Barclays
$35.00
(was $17.44)
Barclays
Syndax price target raised to $38 from $35 at UBS
$38.00
(was $13.76)
UBS
Syndax price target raised to $22 from $19 at Barclays
$22.00
(was $13.76)
Peter Lawson
·
Barclays
Syndax resumed with a Buy at Stifel
$44.00
(was $15.73)
Stifel Nicolaus
Syndax price target lowered to $35 from $37 at UBS
$35.00
(was $9.79)
David Dai
·
UBS
Syndax initiated with a Buy at Goldman Sachs
$18.00
(was $9.82)
Corinne Johnson
·
Goldman Sachs
Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank
$18.00
(was $20.04)
George Farmer
·
Scotiabank
UBS Starts Syndax Pharmaceuticals (SNDX) at Buy
$37.00
(was $18.54)
David Dai
·
UBS
Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi
$34.00
(was $20.09)
Yigal Nochomovitz
·
Citigroup
Syndax price target raised to $31 from $30 at BofA
$31.00
(was $19.58)
Jason Zemansky
·
Bank of America Securities
Syndax price target raised to $33 from $32 at Barclays
$33.00
(was $19.58)
Peter Lawson
·
Barclays
Syndax Pharmaceuticals (SNDX) PT Lowered to $30 at BofA Securities
$30.00
(was $21.99)
Jason Zemansky
·
Bank of America Securities
Jefferies Starts Syndax Pharmaceuticals (SNDX) at Buy
$37.00
(was $20.32)
Kelly Shi
·
Jefferies
Syndax Pharmaceuticals (SNDX) PT Raised to $40 at Stifel
$40.00
(was $22.38)
Bradley Canino
·
Stifel Nicolaus
JP Morgan Initiates Coverage On Syndax Pharmaceuticals with Overweight Rating, Announces Price Target of $41
$41.00
(was $26.32)
J.P. Morgan